CSL Ltd
XMUN:CSJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CSL Ltd
XMUN:CSJ
|
AU |
|
B
|
Bourse Direct SA
SWB:BD6
|
FR |
|
N
|
Naspers Ltd
SWB:NNWN
|
ZA |
|
Y
|
Yokohama Rubber Co Ltd
F:YRB
|
JP |
|
A
|
Amazon.com Inc
XHAM:AMZ
|
US |
|
A
|
Amkor Technology Inc
SWB:AMK
|
US |
|
Schibsted ASA
OSE:VENDB
|
NO |
|
S
|
Sealed Air Corp
SWB:SDA
|
US |
|
C
|
Cisco Systems Inc
SWB:CIS
|
US |
|
M
|
Microsoft Corp
SGO:MSFT
|
US |
|
A
|
ABOUT YOU Holding SE
XMUN:YOU
|
DE |
|
DXP Enterprises Inc
NASDAQ:DXPE
|
US |
|
G
|
Givaudan SA
F:GIN
|
CH |
CSL Ltd
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business. Its customers are hospitals, clinics, blood plasma centers, doctors, public health agencies, and patients who need long-term treatment. CSL makes money by selling prescription medicines and vaccines through healthcare systems and distributors, with sales supported by contracts, tenders, and recurring demand for chronic therapies. A key part of its business is collecting plasma, turning it into purified therapies, and supplying those products to markets where there are few direct substitutes. What makes CSL different is that it sits in a highly specialized part of healthcare where safety, manufacturing skill, and access to plasma matter as much as research. It does not sell ordinary consumer products; it turns complex biological inputs into medicines that are hard to make and are often used for serious, ongoing medical needs. That gives CSL a role as a critical supplier to the healthcare system rather than a broad drugmaker focused on many small molecules.
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business.
Its customers are hospitals, clinics, blood plasma centers, doctors, public health agencies, and patients who need long-term treatment. CSL makes money by selling prescription medicines and vaccines through healthcare systems and distributors, with sales supported by contracts, tenders, and recurring demand for chronic therapies. A key part of its business is collecting plasma, turning it into purified therapies, and supplying those products to markets where there are few direct substitutes.
What makes CSL different is that it sits in a highly specialized part of healthcare where safety, manufacturing skill, and access to plasma matter as much as research. It does not sell ordinary consumer products; it turns complex biological inputs into medicines that are hard to make and are often used for serious, ongoing medical needs. That gives CSL a role as a critical supplier to the healthcare system rather than a broad drugmaker focused on many small molecules.
Profit Decline: Reported net profit after tax fell 81% due to one-off transformation costs and asset impairments, despite underlying business progress.
Revenue Drop: Group revenue for the half was $8.3 billion, down 4% on a constant currency basis.
Guidance Maintained: CSL kept its full-year guidance unchanged, expressing confidence in a stronger second half, particularly in Ig and albumin products.
Transformation Progress: The company is ahead on restructuring and cost-saving initiatives, expanding its cost-saving target and share buyback program.
Segment Performance: Strong nephrology growth offset declines in iron and albumin; new product launches such as HEMGENIX and ANDEMBRY showed positive momentum.
Seqirus Resilience: Seqirus grew market share despite industry headwinds and a normalization of pandemic-related revenues.
Commercial Investments: Expanded sales forces and commercial efforts, especially in the U.S. and China, are expected to drive a recovery in key product areas.
Management
Dr. Paul F. McKenzie is a highly regarded professional in the biotechnology and pharmaceutical industries. He serves as the Chief Executive Officer and Managing Director of CSL Ltd, a leading global biotechnology company. Dr. McKenzie joined CSL in 2019, initially serving in leadership roles such as Chief Operating Officer, where he was responsible for overseeing the company's global end-to-end operations, including manufacturing, quality, engineering, and supply chain management. Before joining CSL, Dr. McKenzie held several senior leadership roles in other major pharmaceutical companies. He was Executive Vice President of Pharmaceutical Operations & Technology at Biogen, where he led global manufacturing, technical operations, quality, and engineering. Dr. McKenzie also worked at Johnson & Johnson and Merck & Co., contributing to various development and manufacturing processes. Dr. McKenzie holds a Ph.D. in Chemical Engineering from Carnegie Mellon University and a Bachelor of Science in Chemical Engineering from the University of Pennsylvania. With his extensive experience and expertise in the biotech and pharmaceutical sectors, Dr. McKenzie is known for his commitment to operational excellence and innovation. His leadership at CSL is focused on advancing the company's key areas of research, development, and global operations, contributing to its mission of delivering innovative medicines to improve patients' lives.
Before joining CSL, Dr. McKenzie held several senior leadership roles in other major pharmaceutical companies. He was Executive Vice President of Pharmaceutical Operations & Technology at Biogen, where he led global manufacturing, technical operations, quality, and engineering. Dr. McKenzie also worked at Johnson & Johnson and Merck & Co., contributing to various development and manufacturing processes.
Dr. McKenzie holds a Ph.D. in Chemical Engineering from Carnegie Mellon University and a Bachelor of Science in Chemical Engineering from the University of Pennsylvania. With his extensive experience and expertise in the biotech and pharmaceutical sectors, Dr. McKenzie is known for his commitment to operational excellence and innovation. His leadership at CSL is focused on advancing the company's key areas of research, development, and global operations, contributing to its mission of delivering innovative medicines to improve patients' lives.
Joy Carolyn Linton is a seasoned executive with a robust background in finance and strategic leadership. She served as the Chief Financial Officer (CFO) for CSL Limited, a leading global biotechnology company known for its innovative biopharmaceuticals and vaccines. Joy Linton brought to her role a wealth of experience in financial management, commercial strategy, and corporate governance. She holds a Bachelor of Commerce degree and further honed her expertise with a Graduate Diploma in Applied Finance and Investment. Joy is also a Graduate of the Australian Institute of Company Directors (GAICD), which underscores her commitment to effective corporate governance and leadership. Prior to joining CSL, Joy Linton held prominent roles, including significant positions at Bupa, one of the largest healthcare companies, where she was involved in finance and operations. Her career reflects a trajectory of success in guiding financial strategy and fostering business growth across various sectors. At CSL, as CFO, Joy Linton played a crucial role in steering the company's financial health, contributing to strategic decisions, and ensuring robust financial governance, which are essential for the company’s sustainable growth and innovation in the biotech industry.
She holds a Bachelor of Commerce degree and further honed her expertise with a Graduate Diploma in Applied Finance and Investment. Joy is also a Graduate of the Australian Institute of Company Directors (GAICD), which underscores her commitment to effective corporate governance and leadership.
Prior to joining CSL, Joy Linton held prominent roles, including significant positions at Bupa, one of the largest healthcare companies, where she was involved in finance and operations. Her career reflects a trajectory of success in guiding financial strategy and fostering business growth across various sectors.
At CSL, as CFO, Joy Linton played a crucial role in steering the company's financial health, contributing to strategic decisions, and ensuring robust financial governance, which are essential for the company’s sustainable growth and innovation in the biotech industry.
Andy Schmeltz does not appear to be associated with CSL Ltd. However, he is known for his role at Pfizer, where he has made significant contributions to the pharmaceutical industry. Andy Schmeltz is recognized for his leadership and strategic vision. He has held various positions at Pfizer, contributing to the company's growth and innovation in healthcare. His work typically involves overseeing significant business operations, developing strategies for growth, and ensuring the delivery of innovative health solutions to meet global needs. If he's currently involved with CSL Ltd or any recent changes have occurred, that information might not be widely documented or publicly available. If you need insights into a different executive or more specific details, additional context would help narrow down the search.
John A. G. Levy CPA is known as the Chief Financial Officer (CFO) of CSL Ltd, a leading global biotechnology company that develops and delivers innovative biotherapies and influenza vaccines. As CFO, Levy is responsible for managing the company’s financial actions, ensuring robust financial health, and providing strategic financial guidance to support CSL’s growth and operational excellence. Levy brings a wealth of experience in financial management and strategic planning to CSL Ltd, having held numerous leadership positions in major organizations before joining CSL. His qualifications as a CPA (Certified Public Accountant) contribute to his expertise in overseeing financial operations, including budgeting, forecasting, taxation, and investor relations. Throughout his career, Levy has been recognized for his ability to effectively navigate complex financial challenges and drive value creation within large, multinational corporations. His leadership at CSL is instrumental in maintaining the company's strong financial performance and supporting its mission to develop innovative healthcare solutions worldwide.
Levy brings a wealth of experience in financial management and strategic planning to CSL Ltd, having held numerous leadership positions in major organizations before joining CSL. His qualifications as a CPA (Certified Public Accountant) contribute to his expertise in overseeing financial operations, including budgeting, forecasting, taxation, and investor relations.
Throughout his career, Levy has been recognized for his ability to effectively navigate complex financial challenges and drive value creation within large, multinational corporations. His leadership at CSL is instrumental in maintaining the company's strong financial performance and supporting its mission to develop innovative healthcare solutions worldwide.
Christopher J. Cooper is an accomplished executive known for his leadership and expertise in the biotechnology and pharmaceutical industries. At CSL Limited, a leading global biotech company that specializes in innovative medicines, Chris Cooper has played a significant role. As an executive at CSL, he has contributed to the company's growth and strategic initiatives. CSL is renowned for its work in areas like immunology, hematology, cardiovascular and metabolic, respiratory, and vaccines. With a focus on research and development, CSL has been at the forefront of delivering cutting-edge therapies to improve patient outcomes across the globe. Chris Cooper’s involvement with CSL underscores his commitment to advancing healthcare solutions through innovation and operational excellence.
Gregory Boss is a well-regarded executive known for his role at CSL Ltd, where he has served in significant leadership capacities. He holds dual Bachelor's degrees in Science and a Juris Doctor, which have underscored his strong foundation both in the scientific and legal arenas. At CSL Ltd, he has been instrumental in guiding the company's strategic direction, particularly in navigating the complex regulatory landscape of the pharmaceutical industry. His expertise in legal affairs and governance has contributed significantly to the company's global operations and compliance strategies. Known for his analytical and leadership skills, Gregory Boss has played a key role in advancing CSL Ltd's mission to deliver innovative biopharmaceutical solutions globally.
Roanne Parry is an executive at CSL Ltd, a global biotechnology company. She holds the position of Senior Vice President for Commercial Development. Parry is responsible for driving commercial strategy and development to support the company's growth objectives. She brings extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership roles focused on marketing, commercial operations, and strategic planning. Her expertise is vital in advancing CSL Ltd's portfolio and expanding its impact in global markets. Parry is recognized for her strategic vision and ability to lead cross-functional teams effectively.
Dr. Andrew D. Nash is a well-respected figure in the biopharmaceutical industry, with significant contributions in the field of medical research and development. At CSL Limited, a leading global biotechnology company, he has held key leadership roles, contributing to the company's strategic direction and success in delivering innovative medicines. Dr. Nash holds a Bachelor of Science with Honors and a Ph.D., highlighting his extensive academic background in scientific research. Additionally, he is a Graduate of the Australian Institute of Company Directors (GAICD), which underscores his competencies in corporate governance and leadership. In his professional career at CSL, Dr. Nash has been instrumental in overseeing research and development initiatives. His work has focused on advancing the company's pipeline of therapeutics and driving innovation in areas such as immunology, hematology, and other critical fields of medicine. Dr. Nash has a strong reputation for fostering collaborations and partnerships that enhance CSL's research capabilities and expand its global reach. His dedication to translating scientific discoveries into real-world treatments has made a significant impact on the healthcare industry and improved patient outcomes worldwide.
Dr. Nash holds a Bachelor of Science with Honors and a Ph.D., highlighting his extensive academic background in scientific research. Additionally, he is a Graduate of the Australian Institute of Company Directors (GAICD), which underscores his competencies in corporate governance and leadership.
In his professional career at CSL, Dr. Nash has been instrumental in overseeing research and development initiatives. His work has focused on advancing the company's pipeline of therapeutics and driving innovation in areas such as immunology, hematology, and other critical fields of medicine.
Dr. Nash has a strong reputation for fostering collaborations and partnerships that enhance CSL's research capabilities and expand its global reach. His dedication to translating scientific discoveries into real-world treatments has made a significant impact on the healthcare industry and improved patient outcomes worldwide.
Dr. William Mezzanotte is an accomplished medical professional and executive with extensive experience in the pharmaceutical and biotechnology industries. He serves as the Executive Vice President, Head of Research and Development, and Chief Medical Officer at CSL Limited, a global biotech company known for its innovative medicines and therapies in areas such as immunology and hematology. Dr. Mezzanotte joined CSL Limited in 2017, bringing with him a wealth of experience from leadership roles in various healthcare companies. Prior to his tenure at CSL, he held significant positions at AstraZeneca, where he was responsible for late-stage development of respiratory, inflammation, and autoimmunity products. His work has consistently focused on leading teams in the development of critical care medicines and advancing clinical research. In addition to his industry roles, Dr. Mezzanotte holds an M.D. (Doctor of Medicine) and an M.P.H. (Master of Public Health), underscoring his deep expertise in both medical practice and public health matters. His leadership at CSL involves steering the company's R&D activities, driving innovation in biotech solutions, and contributing to the company's strategic efforts to address unmet medical needs globally. Dr. Mezzanotte is recognized for his strategic vision and his ability to foster scientific advancements that translate into real-world medical solutions, enhancing CSL's contributions to healthcare and improving patient outcomes around the world.
Dr. Mezzanotte joined CSL Limited in 2017, bringing with him a wealth of experience from leadership roles in various healthcare companies. Prior to his tenure at CSL, he held significant positions at AstraZeneca, where he was responsible for late-stage development of respiratory, inflammation, and autoimmunity products. His work has consistently focused on leading teams in the development of critical care medicines and advancing clinical research.
In addition to his industry roles, Dr. Mezzanotte holds an M.D. (Doctor of Medicine) and an M.P.H. (Master of Public Health), underscoring his deep expertise in both medical practice and public health matters. His leadership at CSL involves steering the company's R&D activities, driving innovation in biotech solutions, and contributing to the company's strategic efforts to address unmet medical needs globally.
Dr. Mezzanotte is recognized for his strategic vision and his ability to foster scientific advancements that translate into real-world medical solutions, enhancing CSL's contributions to healthcare and improving patient outcomes around the world.
Mark Hill is a well-regarded executive with a distinguished career at CSL Ltd, a leading global biotechnology company specializing in the development and delivery of innovative biopharmaceutical products. Holding a Bachelor of Arts as well as a Master of Business Administration, Mark Hill has contributed significantly to CSL’s strategic growth and operational excellence. In his role at CSL, Mark Hill has been instrumental in steering the company through various market dynamics and industry challenges. His expertise in business strategy, coupled with his leadership skills, has supported CSL's expansion and sustained its position as a key player in the biotech space. His efforts have been pivotal in driving initiatives that enhance product development and market penetration, ensuring that CSL continues to deliver value to its stakeholders. Mark Hill is known for his forward-thinking approach and his ability to foster a culture of innovation and efficiency within the company. His contributions extend beyond day-to-day operations to include mentorship and the development of future leaders within CSL. Hill's impact is marked by a dedication to both the scientific and commercial aspects of the biotechnology field, aligning with CSL's mission to save lives and protect the health of patients worldwide.
In his role at CSL, Mark Hill has been instrumental in steering the company through various market dynamics and industry challenges. His expertise in business strategy, coupled with his leadership skills, has supported CSL's expansion and sustained its position as a key player in the biotech space. His efforts have been pivotal in driving initiatives that enhance product development and market penetration, ensuring that CSL continues to deliver value to its stakeholders.
Mark Hill is known for his forward-thinking approach and his ability to foster a culture of innovation and efficiency within the company. His contributions extend beyond day-to-day operations to include mentorship and the development of future leaders within CSL. Hill's impact is marked by a dedication to both the scientific and commercial aspects of the biotechnology field, aligning with CSL's mission to save lives and protect the health of patients worldwide.
